PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

Trial Profile

PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PROMOTE
  • Most Recent Events

    • 05 Jun 2018 Results of a transcriptome analysis assessing predictor of response to abiraterone acetate/prednisone (n=58), presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 31 Oct 2017 New trial record
    • 23 Oct 2017 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top